Systematic Reviewhigh evidence
Cannabinoid exposure across substance use disorders: Short-term symptom benefits without sustained therapeutic gains in a tier-weighted systematic review.
European psychiatry : the journal of the Association of European Psychiatrists·July 17, 2026·PMID 42466639
Why it mattersClinicians treating SUDs frequently encounter patient interest in cannabinoids as adjunctive therapy. This review clarifies that any benefits are limited to transient symptom reduction, not durable recovery endpoints, helping guide evidence-based counseling and treatment planning.
The papers that matter, first.
MedLit ranks the medical literature into a specialty feed with concise summaries, evidence-aware triage, and visual takeaways.
§
MedLit · Evidence, Distilled